Rheumatoid Arthritis Drugs Show Promise for Long Covid Relief

A new study reveals that drugs used to treat rheumatoid arthritis may alleviate lung-related symptoms in long Covid patients. Researchers from the University of Virginia found that Covid-19 can cause persistent lung inflammation, leading to respiratory issues. Anti-inflammatory drugs like baricitinib could potentially interrupt this cycle, with clinical trials necessary for confirmation.

A new study suggests that rheumatoid arthritis drugs could alleviate lung-related symptoms in long Covid patients, which can linger even two years post-infection.

Published in the journal Science Translational Medicine, the research examined lung tissues from both mice and humans, uncovering that Covid-19 causes changes in immune cells that promote lung scarring and inflammation long after the initial infection.

The persisting inflammation may contribute to long-lasting respiratory symptoms such as coughing and difficulty breathing. Researchers from the University of Virginia propose that the anti-inflammatory effects of rheumatoid arthritis drugs like baricitinib might relieve these symptoms. However, they emphasize that clinical trials are needed to validate these findings.

(With inputs from agencies.)